New AI Test for Prostate Cancer Therapy Enters US Market

Florida-based medical tech firm ArteraAI has developed the ArteraAI Prostate Test, the first predictive test for patients with localized prostate cancer. The test uses AI to analyze a biopsy of the cancerous tumor and certain clinical data to predict the likely outcomes for the patient and help the physician determine the optimal therapy. The test offers fast turnaround times and complements healthcare providers' work. While AI shows promise in healthcare, there is a need to protect patients' privacy and security and ensure the data represents the entire population it's intended to treat.